论文部分内容阅读
目的 探讨短期新辅助内分泌治疗对前列腺癌神经内分泌分化的影响 ,以及神经内分泌分化程度和肿瘤退化程度的关系。方法 采用嗜铬素A(ChA)和 5 羟色胺特异性免疫抗体作为神经内分泌细胞标记物 ,分析 18例前列腺癌患者内分泌治疗前后神经内分泌分化程度的差异。结果治疗前后 ,癌灶内神经内分泌肿瘤细胞数分别为 3.2× 10 5/ μm2 [(0～ 5 .7)× 10 5/ μm2 ]和 2 .3× 10 5/ μm2[(0～ 6 .6 )× 10 5/ μm2 ],差异无显著性 (P >0 .0 5 )。治疗前后神经内分泌肿瘤细胞百分比分别为7.0 % (0 %～ 14 .9% )和 4 .5 % (0 %～ 13.1% ) ,差异无显著性 (P >0 .0 5 )。 6例肿瘤中重度退化者与12例无退化或轻微退化者相比 ,癌灶内神经内分泌肿瘤细胞数差异无显著性 (P >0 .0 5 )。结论 短期新辅助内分泌治疗未导致明显前列腺癌神经内分泌细胞克隆增殖 ,治疗后肿瘤的退化程度和神经内分泌分化程度无明显相关性。
Objective To investigate the effect of short-term neo-adjuvant endocrine therapy on neuroendocrine differentiation of prostate cancer and the relationship between neuroendocrine differentiation and tumor degeneration. Methods Choline and serotonin-specific antibodies were used as neuroendocrine markers to analyze the difference of neuroendocrine differentiation before and after endocrine therapy in 18 patients with prostate cancer. Results Before and after treatment, the number of neuroendocrine tumor cells in the foci was 3.2 × 10 5 / μm 2 [(0-5.7) × 10 5 / μm 2] and 2.3 × 10 5 / μm 2 [(0-6.6 ) × 10 5 / μm 2], no significant difference (P> 0.05). The percentages of neuroendocrine tumor cells before and after treatment were 7.0% (0% -14.9%) and 4.5% (0% -13.1%) respectively, with no significant difference (P> 0.05). There were no significant differences in the number of neuroendocrine tumor cells in 6 cases of severe degenerative tumors compared with 12 cases of degenerated or slightly degenerated cancers (P> 0.05). Conclusions Short-term neoadjuvant endocrine therapy did not result in significant proliferation of neuroendocrine cells in prostate cancer. No significant correlation was found between the degree of tumor degeneration and the degree of neuroendocrine differentiation after treatment.